<clinical_study>
  <!-- This xml conforms to an XML Schema at:
    https://clinicaltrials.gov/ct2/html/images/info/public.xsd -->
  <required_header>
    <download_date>ClinicalTrials.gov processed this data on November 19, 2021</download_date>
    <link_text>Link to the current ClinicalTrials.gov record.</link_text>
    <url>https://clinicaltrials.gov/show/NCT04924062</url>
  </required_header>
  <id_info>
    <org_study_id>3475-966 China Extension</org_study_id>
    <secondary_id>2019-000944-82</secondary_id>
    <secondary_id>MK-3475-966</secondary_id>
    <secondary_id>KEYNOTE-966</secondary_id>
    <secondary_id>195007</secondary_id>
    <nct_id>NCT04924062</nct_id>
  </id_info>
  <brief_title>Pembrolizumab (MK-3475) Plus Gemcitabine/Cisplatin Versus Placebo Plus Gemcitabine/Cisplatin for First-Line Advanced and/or Unresectable Biliary Tract Carcinoma (BTC) (MK-3475-966/KEYNOTE-966)-China Extension Study</brief_title>
  <official_title>A Phase 3 Randomized, Double Blind Study of Pembrolizumab Plus Gemcitabine/Cisplatin Versus Placebo Plus Gemcitabine/Cisplatin as First-Line Therapy in Participants With Advanced and/or Unresectable Biliary Tract Carcinoma</official_title>
  <sponsors>
    <lead_sponsor>
      <agency>Merck Sharp &amp; Dohme Corp.</agency>
      <agency_class>Industry</agency_class>
    </lead_sponsor>
  </sponsors>
  <source>Merck Sharp &amp; Dohme Corp.</source>
  <oversight_info>
    <has_dmc>Yes</has_dmc>
    <is_fda_regulated_drug>Yes</is_fda_regulated_drug>
    <is_fda_regulated_device>No</is_fda_regulated_device>
    <is_us_export>Yes</is_us_export>
  </oversight_info>
  <brief_summary>
    <textblock>
      In this China Extension study, pembrolizumab plus gemcitabine/cisplatin will be compared with&#xD;
      placebo plus gemcitabine/cisplatin as first-line therapy in Chinese adults with advanced&#xD;
      and/or unresectable biliary tract carcinoma. The primary hypothesis is pembrolizumab plus&#xD;
      gemcitabine/cisplatin is superior to placebo plus gemcitabine/cisplatin with respect to&#xD;
      overall survival (OS).&#xD;
    </textblock>
  </brief_summary>
  <detailed_description>
    <textblock>
      The China extension study will include participants previously enrolled in China in the&#xD;
      global study for MK-3475-966 (NCT04003636) plus those enrolled during the China extension&#xD;
      enrollment period. A total of approximately 158 Chinese participants will be enrolled.&#xD;
    </textblock>
  </detailed_description>
  <overall_status>Active, not recruiting</overall_status>
  <start_date type="Actual">July 10, 2020</start_date>
  <completion_date type="Anticipated">December 31, 2023</completion_date>
  <primary_completion_date type="Anticipated">December 31, 2023</primary_completion_date>
  <phase>Phase 3</phase>
  <study_type>Interventional</study_type>
  <has_expanded_access>No</has_expanded_access>
  <study_design_info>
    <allocation>Randomized</allocation>
    <intervention_model>Parallel Assignment</intervention_model>
    <primary_purpose>Treatment</primary_purpose>
    <masking>Triple (Participant, Investigator, Outcomes Assessor)</masking>
  </study_design_info>
  <primary_outcome>
    <measure>Overall Survival (OS)</measure>
    <time_frame>Up to approximately 41 months</time_frame>
    <description>Overall survival is defined as the time from randomization to death due to any cause.</description>
  </primary_outcome>
  <secondary_outcome>
    <measure>Objective Response Rate (ORR) per Response Evaluation Criteria in Solid Tumors Version 1.1 (RECIST 1.1) as Assessed by Blinded Independent Central Review (BICR)</measure>
    <time_frame>Up to approximately 41 months</time_frame>
    <description>ORR is defined as the percentage of participants who have a confirmed Complete Response (CR: disappearance of all target lesions) or Partial Response (PR: a ≥30% decrease in the sum of diameters [SOD] of target lesions) as assessed by BICR per RECIST 1.1, which is adjusted for this study to allow a maximum of 10 target lesions in total and 5 per organ.</description>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Duration of Response (DOR) per RECIST 1.1 as Assessed by BICR</measure>
    <time_frame>Up to approximately 41 months</time_frame>
    <description>For participants who demonstrate a confirmed CR or PR, DOR is the time from the first documented evidence of CR or PR until disease progression or death due to any cause, whichever occurs first.</description>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Number of Participants Who Experience One or More Adverse Events (AE)</measure>
    <time_frame>Up to approximately 41 months</time_frame>
    <description>An adverse event (AE) is defined as any unfavorable and unintended sign including an abnormal laboratory finding, symptom or disease associated with the use of a medical treatment or procedure, regardless of whether it is considered related to the medical treatment or procedure, that occurs during the course of the study.</description>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Number of Participants Who Discontinued Study Intervention Due to an Adverse Event (AE)</measure>
    <time_frame>Up to approximately 41 months</time_frame>
    <description>An AE is defined as any unfavorable and unintended sign including an abnormal laboratory finding, symptom or disease associated with the use of a medical treatment or procedure, regardless of whether it is considered related to the medical treatment or procedure, that occurs during the course of the study.</description>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Progression-free Survival (PFS) per RECIST 1.1 as Assessed by BICR</measure>
    <time_frame>Up to approximately 41 months</time_frame>
    <description>Progression-free survival is defined as the time from randomization to the first documented disease progression or death due to any cause, whichever occurs first.</description>
  </secondary_outcome>
  <number_of_arms>2</number_of_arms>
  <enrollment type="Anticipated">160</enrollment>
  <condition>Biliary Tract Carcinoma</condition>
  <arm_group>
    <arm_group_label>Arm A (Pembrolizumab+Gemcitabine+Cisplatin)</arm_group_label>
    <arm_group_type>Experimental</arm_group_type>
    <description>Pembrolizumab, 200 mg, every 3 weeks (Q3W), Day 1 of each 3-week cycle for up to 35 cycles PLUS Gemcitabine, 1000 mg/m^2, Q3W, Day 1 and Day 8 of each cycle until progressive disease or unacceptable toxicity PLUS Cisplatin, 25 mg/m^2, Q3W, Day 1 and Day 8 of each cycle for up to 8 cycles.</description>
  </arm_group>
  <arm_group>
    <arm_group_label>Arm B (Placebo+Gemcitabine+Cisplatin)</arm_group_label>
    <arm_group_type>Placebo Comparator</arm_group_type>
    <description>Placebo to Pembrolizumab, 200 mg, every 3 weeks (Q3W), Day 1 of each 3-week cycle for up to 35 cycles PLUS Gemcitabine, 1000 mg/m^2, Q3W, Day 1 and Day 8 of each cycle until progressive disease or unacceptable toxicity PLUS Cisplatin, 25 mg/m^2, Q3W, Day 1 and Day 8 of each cycle for up to 8 cycles.</description>
  </arm_group>
  <intervention>
    <intervention_type>Biological</intervention_type>
    <intervention_name>Pembrolizumab</intervention_name>
    <description>Pembrolizumab by intravenous (IV) infusion</description>
    <arm_group_label>Arm A (Pembrolizumab+Gemcitabine+Cisplatin)</arm_group_label>
    <other_name>MK-3475</other_name>
  </intervention>
  <intervention>
    <intervention_type>Drug</intervention_type>
    <intervention_name>Gemcitabine</intervention_name>
    <description>Gemcitabine by IV infusion</description>
    <arm_group_label>Arm A (Pembrolizumab+Gemcitabine+Cisplatin)</arm_group_label>
    <arm_group_label>Arm B (Placebo+Gemcitabine+Cisplatin)</arm_group_label>
    <other_name>Gemzar</other_name>
  </intervention>
  <intervention>
    <intervention_type>Drug</intervention_type>
    <intervention_name>Cisplatin</intervention_name>
    <description>Cisplatin by IV infusion</description>
    <arm_group_label>Arm A (Pembrolizumab+Gemcitabine+Cisplatin)</arm_group_label>
    <arm_group_label>Arm B (Placebo+Gemcitabine+Cisplatin)</arm_group_label>
    <other_name>Platinol®</other_name>
    <other_name>Platinol®-AQ</other_name>
  </intervention>
  <intervention>
    <intervention_type>Drug</intervention_type>
    <intervention_name>Placebo</intervention_name>
    <description>Placebo to pembrolizumab</description>
    <arm_group_label>Arm B (Placebo+Gemcitabine+Cisplatin)</arm_group_label>
  </intervention>
  <eligibility>
    <criteria>
      <textblock>
        Inclusion Criteria&#xD;
&#xD;
          -  Has histologically confirmed diagnosis of advanced (metastatic) and/or unresectable&#xD;
             (locally advanced) biliary tract cancer (intra-or extrahepatic cholangiocarcinoma or&#xD;
             gallbladder cancer)&#xD;
&#xD;
          -  Has measurable disease based on Response Evaluation Criteria in Solid Tumors (RECIST&#xD;
             1.1), as determined by the site investigator&#xD;
&#xD;
          -  Participants with a history of hepatitis B or hepatitis C can be enrolled if they meet&#xD;
             study criteria&#xD;
&#xD;
          -  Is able to provide archival tumor tissue sample or newly obtained core or excisional&#xD;
             biopsy of a tumor lesion&#xD;
&#xD;
          -  Has a life expectancy of greater than 3 months&#xD;
&#xD;
          -  Has adequate organ function&#xD;
&#xD;
        Exclusion Criteria&#xD;
&#xD;
          -  Has had previous systemic therapy for advanced (metastatic) or unresectable (locally&#xD;
             advanced) biliary tract cancer (intra-or extra hepatic cholangiocarcinoma or&#xD;
             gallbladder cancer)&#xD;
&#xD;
          -  Has ampullary cancer&#xD;
&#xD;
          -  Has small cell cancer, neuroendocrine tumors, lymphoma, sarcoma, mixed tumor histology&#xD;
             and/or mucinous cystic neoplasms&#xD;
&#xD;
          -  Has received prior therapy with an anti-programmed cell death 1 (anti-PD-1), anti-&#xD;
             programmed cell death ligand 1 or 2 (anti-PD-L1, anti-PD-L2) agent or with an agent&#xD;
             directed to another stimulatory or coinhibitory T-cell receptor (e.g., cytotoxic&#xD;
             T-lymphocyte-associated protein 4 [CTLA-4], OX-40, CD137)&#xD;
&#xD;
          -  Has a known history of, or any evidence of, central nervous system (CNS) metastases&#xD;
             and/or carcinomatous meningitis, as assessed by local site investigator&#xD;
&#xD;
          -  Has had an allogenic tissue/solid organ transplant&#xD;
      </textblock>
    </criteria>
    <gender>All</gender>
    <minimum_age>18 Years</minimum_age>
    <maximum_age>N/A</maximum_age>
    <healthy_volunteers>No</healthy_volunteers>
  </eligibility>
  <overall_official>
    <last_name>Medical Director</last_name>
    <role>Study Director</role>
    <affiliation>Merck Sharp &amp; Dohme Corp.</affiliation>
  </overall_official>
  <location>
    <facility>
      <name>Anhui Provincial Hospital ( Site 0140)</name>
      <address>
        <city>Hefei</city>
        <state>Anhui</state>
        <zip>230001</zip>
        <country>China</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Beijing Cancer Hospital ( Site 0138)</name>
      <address>
        <city>Beijing</city>
        <state>Beijing</state>
        <zip>100036</zip>
        <country>China</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Peking Union Medical College Hospital ( Site 0150)</name>
      <address>
        <city>Beijing</city>
        <state>Beijing</state>
        <zip>100730</zip>
        <country>China</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>First Affiliated Hospital of The Third Military Medical University ( Site 0130)</name>
      <address>
        <city>Chongqing</city>
        <state>Chongqing</state>
        <zip>400038</zip>
        <country>China</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Fujian Provincial Cancer Hospital ( Site 0154)</name>
      <address>
        <city>Fuzhou</city>
        <state>Fujian</state>
        <zip>350014</zip>
        <country>China</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>900 Hospital of the Joint ( Site 0137)</name>
      <address>
        <city>Fuzhou</city>
        <state>Fujian</state>
        <zip>350025</zip>
        <country>China</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Guangdong Provincial People s Hospital ( Site 0161)</name>
      <address>
        <city>Guangzhou</city>
        <state>Guangdong</state>
        <zip>510080</zip>
        <country>China</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Harbin Medical University Cancer Hospital ( Site 0133)</name>
      <address>
        <city>Harbin</city>
        <state>Heilongjiang</state>
        <zip>610000</zip>
        <country>China</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Hunan Provincial People Hospital ( Site 0142)</name>
      <address>
        <city>Changsha</city>
        <state>Hunan</state>
        <zip>410005</zip>
        <country>China</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Hunan Cancer Hospital ( Site 0132)</name>
      <address>
        <city>Changsha</city>
        <state>Hunan</state>
        <zip>410013</zip>
        <country>China</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>The Third Xiangya Hospital of Central South University ( Site 0157)</name>
      <address>
        <city>Changsha</city>
        <state>Hunan</state>
        <zip>410013</zip>
        <country>China</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>The 81st Hospital of PLA ( Site 0128)</name>
      <address>
        <city>Nanjing</city>
        <state>Jiangsu</state>
        <zip>210031</zip>
        <country>China</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>The First Hospital of Jilin University ( Site 0131)</name>
      <address>
        <city>Chanchun</city>
        <state>Jilin</state>
        <zip>130021</zip>
        <country>China</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Zhongshan Hospital Fudan University ( Site 0129)</name>
      <address>
        <city>Shanghai</city>
        <state>Shanghai</state>
        <zip>200032</zip>
        <country>China</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Renji Hospital Shanghai Jiaotong University School of Medicine ( Site 0158)</name>
      <address>
        <city>Shanghai</city>
        <state>Shanghai</state>
        <zip>200127</zip>
        <country>China</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Fudan University Shanghai Cancer Center ( Site 0160)</name>
      <address>
        <city>Shanghai</city>
        <state>Shanghai</state>
        <zip>201315</zip>
        <country>China</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Tangdu Hospital ( Site 0146)</name>
      <address>
        <city>XI An</city>
        <state>Shanxi</state>
        <zip>710038</zip>
        <country>China</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>The First Affiliated Hospital of Xi an Jiaotong University ( Site 0145)</name>
      <address>
        <city>XI An</city>
        <state>Shanxi</state>
        <zip>710048</zip>
        <country>China</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>West China Hospital of Sichuan University ( Site 0147)</name>
      <address>
        <city>Chengdu</city>
        <state>Sichuan</state>
        <zip>610041</zip>
        <country>China</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Tianjin Medical University Cancer Institute &amp; Hospital ( Site 0155)</name>
      <address>
        <city>Tianjin</city>
        <state>Tianjin</state>
        <zip>300060</zip>
        <country>China</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>The First Affiliated Hospital Zhejiang University ( Site 0136)</name>
      <address>
        <city>Hangzhou</city>
        <state>Zhejiang</state>
        <zip>310003</zip>
        <country>China</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Zhejiang Cancer Hospital ( Site 0134)</name>
      <address>
        <city>Hangzhou</city>
        <state>Zhejiang</state>
        <zip>310022</zip>
        <country>China</country>
      </address>
    </facility>
  </location>
  <location_countries>
    <country>China</country>
  </location_countries>
  <link>
    <url>http://merckoncologyclinicaltrials.com</url>
    <description>Merck Oncology Clinical Trials Information</description>
  </link>
  <verification_date>September 2021</verification_date>
  <study_first_submitted>June 8, 2021</study_first_submitted>
  <study_first_submitted_qc>June 8, 2021</study_first_submitted_qc>
  <study_first_posted type="Actual">June 11, 2021</study_first_posted>
  <last_update_submitted>September 16, 2021</last_update_submitted>
  <last_update_submitted_qc>September 16, 2021</last_update_submitted_qc>
  <last_update_posted type="Actual">September 22, 2021</last_update_posted>
  <responsible_party>
    <responsible_party_type>Sponsor</responsible_party_type>
  </responsible_party>
  <keyword>Programmed cell death 1 (PD-1)</keyword>
  <keyword>Pembrolizumab</keyword>
  <keyword>Cholangiocarcinoma</keyword>
  <keyword>Gallbladder cancer</keyword>
  <keyword>Checkpoint inhibitor</keyword>
  <keyword>Immunotherapy</keyword>
  <keyword>Biliary</keyword>
  <keyword>Keytruda</keyword>
  <keyword>Bile Duct Cancer</keyword>
  <condition_browse>
    <!-- CAUTION:  The following MeSH terms are assigned with an imperfect algorithm            -->
    <mesh_term>Carcinoma</mesh_term>
  </condition_browse>
  <intervention_browse>
    <!-- CAUTION:  The following MeSH terms are assigned with an imperfect algorithm            -->
    <mesh_term>Gemcitabine</mesh_term>
    <mesh_term>Cisplatin</mesh_term>
    <mesh_term>Pembrolizumab</mesh_term>
  </intervention_browse>
  <patient_data>
    <sharing_ipd>Yes</sharing_ipd>
    <ipd_description>http://engagezone.msd.com/doc/ProcedureAccessClinicalTrialData.pdf</ipd_description>
    <ipd_url>http://engagezone.msd.com/ds_documentation.php</ipd_url>
  </patient_data>
  <!-- Results have not yet been posted for this study                                          -->
</clinical_study>

